Adalimumab plus Methotrexate for Uveitis in Juvenile Idiopathic Arthritis | Zendy

Athimalaipet V Ramanan | Zendy; Andrew D. Dick | Zendy; Ashley P Jones | Zendy; Andrew McKay | Zendy; Paula Williamson | Zendy; Sandrine CompeyrotLacassagne | Zendy; Ben Hardwick | Zendy; Helen Hickey | Zendy; Dyfrig Hughes | Zendy; Patricia Woo | Zendy; Diana Benton | Zendy; Clive Edelsten | Zendy; Michael W. Beresford | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Adalimumab plus Methotrexate for Uveitis in Juvenile Idiopathic Arthritis

Author(s) -

Athimalaipet V Ramanan,

Andrew D. Dick,

Ashley P Jones,

Andrew McKay,

Paula Williamson,

Sandrine CompeyrotLacassagne,

Ben Hardwick,

Helen Hickey,

Dyfrig Hughes,

Patricia Woo,

Diana Benton,

Clive Edelsten,

Michael W. Beresford

Publication year - 2017

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1614160

Subject(s) - medicine , adalimumab , uveitis , placebo , hazard ratio , adverse effect , regimen , randomization , surgery , randomized controlled trial , confidence interval , rheumatoid arthritis , immunology , alternative medicine , pathology

Adalimumab, a fully human anti-tumor necrosis factor α monoclonal antibody, is effective in the treatment of juvenile idiopathic arthritis (JIA). We tested the efficacy of adalimumab in the treatment of JIA-associated uveitis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research